La catena delle opzioni mostra i dati chiave delle opzioni azionarie di Tharimmune a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per Tharimmune..

Tharimmune (NASDAQ:THAR) Azioni, Catena delle Opzioni

Tharimmune

Tharimmune Inc is a biotechnology company developing a portfolio of therapeutic candidates for rare immune, inflammatory, and oncologic diseases. The Company is progressing towards acquiring a clinical-stage asset, known to suppress chronic, debilitating pruritis or uncontrollable itching in primary biliary cholangitis (PBC), a rare orphan liver disease with no known cure. The Company's early-stage immuno-oncology pipeline includes novel multi-specific antibodies targeting epitopes with novel mechanisms of action against validated targets in multiple solid tumors.

Tharimmune Inc

Tharisa PLC

B of A Securities analyst Ross Fowler upgrades Idacorp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IDA#NYSE">IDA</a>) from Neutral to Buy and raises the price target from $113 to $117.

News

Upgrades

Price Target

Analyst Ratings

B of A Securities Upgrades Idacorp to Buy, Raises Price Target to $117

Contracts

RDWR

Radware Expands Customer Relationship With A Prominent US Based Communications Platform As A Service Provider In Multimillion-Dollar Deal

Emeren Enters Co-Development Agreement With Arpinge To Jointly Develop A 300 MW Battery Energy Storage System Portfolio In Southern Italy

Taiwan Semiconductor Manufacturing Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TSM#NYSE">TSM</a>) remains vulnerable to Taiwan&#8217;s surging electricity prices, a shift that could impact the semiconductor industry.
Once a competitive edge, Taiwan&#8217;s low-cost energy has become more challenging to maintain, leading to increased costs for major industrial consumers, the Financial Times <a target="_blank" href="https://www.ft.com/content/cfd77e84-5d5b-47ae-96bd-9973b1c18662" rel="noreferrer noopener">reports</a>.
Taiwan Semiconductor now anticipates that electricity expenses in Taiwan will surpass those in its other significant locations, including the U.S., Japan, and Germany.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/24/10/41633790/apple-refreshes-macbook-pro-lineup-with-m4-pro-and-m4-max-3nm-chips" rel="noreferrer noopener">Apple Refreshes MacBook Pro Lineup With M4 Pro and M4 Max 3Nm Chips</a>
<a target="_blank" href="https://www.benzinga.com/markets/equities/24/11/41706702/nvidia-supplier-tsmc-to-double-advanced-chip-packaging-capacity-as-ai-demand-from-microsoft-amaz" rel="noreferrer noopener">Recent reports indicated</a> the chipmaker will double its advanced packaging capacity by 2025, largely to meet the rising demand for AI chips from major tech firms like Nvidia Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) and Microsoft Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>). The company&#8217;s CoWoS packaging technology is in high demand, with Nvidia expected to use more than half of the expanded capacity.
CFO Wendell Huang recently disclosed to investors that power costs in Taiwan have effectively doubled over the past few years and will likely be Taiwan Semiconductor&#8217;s highest globally by 2024.
Taiwan&#8217;s government has raised electricity prices four times since 2022, with increases primarily affecting industrial users like Taiwan Semiconductor.
In line with its broader energy transition, Taiwan aims to boost renewable energy to supply up to 30% of its power by 2030. However, a recent emphasis on scaling back coal and nuclear power has made it increasingly challenging to meet industrial demands.
According to FT, Taiwan relies on coal and liquefied natural gas for over 80% of its energy supply, with renewable sources accounting for only 9.5%.
The rising electricity rates alone may not significantly hinder Taiwan Semiconductor&#8217;s operations, as power costs constitute a minor portion of its overall expenses. However, consistent supply disruptions could threaten Taiwan Semiconductor&#8217;s ability to expand its production capacity in Taiwan, FT writes.
Taiwan Semiconductor stock has gained 89% year-to-date. Investors can gain exposure to the stock through the iShares Semiconductor ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOXX#NASDAQ">SOXX</a>) and the First Trust NASDAQ Technology Dividend Index Fund (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TDIV#NASDAQ">TDIV</a>).
Price Actions:&nbsp;TSM stock traded higher by 1.17% to $193.80 premarket at the last check on Tuesday.
Also Read:
<ul>
<li><a href="https://www.benzinga.com/government/24/11/41726213/applied-materials-and-lam-research-shift-supply-chains-away-from-china-to-meet-new-us-guidelines" target="_blank" rel="noreferrer noopener">Applied Materials and Lam Research Shift Supply Chains Away from China to Meet New US Guidelines</a></li>
</ul>
Photo by wakamatsu.h via Shutterstock

Government

Regulations

Tech

Media

MSFT

NVDA

iShares PHLX SOX Semiconductor Sector Index Fund

SOXX

TDIV

Taiwan Semiconductor Faces Rising Energy Costs, Potential Outages Threaten Production

As the United States approaches the election, Trump Media &amp; Technology Group Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DJT#NASDAQ">DJT</a>) has seen a notable 5.15% increase in pre-market trading on Tuesday, as per <a href="https://pro.benzinga.com">Benzinga Pro</a>. This surge comes as traders perceive the company&#8217;s stock as a potential indicator of Donald Trump&#8217;s reelection chances.
What Happened: The recent uptick in Trump Media &amp; Technology Group&#8217;s stock is linked to the upcoming U.S. elections. On Monday, DJT closed 12.37% higher at $34.34.
Traders are treating Trump&#8217;s stock as a gauge for his reelection prospects. If Trump wins, his platform, Truth Social, is expected to play a significant role in his communication strategy, akin to his use of X during his presidency, according to <a href="https://www.cnbctv18.com/world/share-of-donald-trumps-social-media-firm-surge-on-eve-of-the-us-election-day-19503834.htm">CNBC</a>. However, if Vice President Kamala Harris wins, the future of Truth Social could face challenges.
See Also: <a href="https://www.benzinga.com/news/24/11/41710411/market-analyst-who-predicted-trumps-2016-win-and-bidens-2020-victory-now-sees-former-president-retak?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Market Analyst Who Predicted Trump&#8217;s 2016 Win And Biden&#8217;s 2020 Victory, Now Sees Former President Retaking The White House With &#8216;Large Majority Of Swing States&#8217;</a>
This development is occurring as the nation gears up for a pivotal election, with market participants closely watching political dynamics. The performance of Trump Media &amp; Technology Group&#8217;s stock reflects broader sentiments regarding the election&#8217;s potential outcomes and their implications for Trump&#8217;s media ventures.
Why It Matters: The election race between Trump and Harris has tightened, with recent polls showing <a href="https://www.benzinga.com/general/politics/24/11/41733277/harris-vs-trump-vice-president-has-two-point-lead-in-final-election-poll-swing-states-remain-clo">Harris maintaining a slight lead</a> over Trump. However, her lead has been shrinking, indicating a closely contested election. This uncertainty adds to the volatility surrounding Trump Media &amp; Technology Group&#8217;s stock.
Additionally, options activity for <a href="https://www.benzinga.com/insights/options/24/11/41717863/this-is-what-whales-are-betting-on-trump-media-technology">Trump Media &amp; Technology</a> has seen significant movement, with deep-pocketed investors showing a divided sentiment. While 36% of these investors are bullish, 48% are bearish, indicating mixed expectations about the company&#8217;s future. 
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/asia/24/11/41722178/if-trump-and-republicans-sweep-dollar-may-climb-7-but-harris-win-could-bring-5-drop-says-jpmorgan?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">If Trump And Republicans Sweep, Dollar May Climb 7% — But Harris Win Could Bring 5% Drop, Says JPMorgan</a></li>
</ul>
Disclaimer: This content was partially produced with the help of&nbsp;<a href="https://www.benzinga.com/author/benzinga-neuro" target="_blank" rel="noreferrer noopener">Benzinga Neuro</a>&nbsp;and was reviewed and published by Benzinga editors.
Image via Shutterstock

Equities

Pre-Market Outlook

Markets

General

Trump Media (DJT) Stock Rises Over 6% In Pre-Market Ahead Of Presidential Election Eve

Vishay Precision Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VPG#NYSE">VPG</a>) sees Q4 sales of $70.000 million-78.000 million vs $79.10 million estimate.

Guidance

Vishay Precision Group Sees Q4 Sales $70.000M-78.000M vs $79.10M Est

TD Cowen analyst Bill Katz downgrades Affiliated Managers Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMG#NYSE">AMG</a>) from Buy to Hold and lowers the price target from $226 to $177.

Downgrades

TD Cowen Downgrades Affiliated Managers Group to Hold, Lowers Price Target to $177

Vishay Precision Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VPG#NYSE">VPG</a>) reported quarterly earnings of $0.19 per share which missed the analyst consensus estimate of $0.26 by 26.92 percent. This is a 59.57 percent decrease over earnings of $0.47 per share from the same period last year. The company reported quarterly sales of $75.73 million which missed the analyst consensus estimate of $76.71 million by 1.28 percent. This is a 11.80 percent decrease over sales of $85.85 million the same period last year.

Earnings

Earnings Misses

Vishay Precision Group Q3 Adj $0.19 Misses $0.26 Estimate, Sales $75.73M Miss $76.71M Estimate

CRVL

CorVel Q2 EPS $1.35 Up From $1.15 YoY, Sales $224M Up From $196M YoY

Deutsche Bank analyst Bryan Keane downgrades Marqeta (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MQ#NASDAQ">MQ</a>) from Buy to Hold and lowers the price target from $9 to $4.

Deutsche Bank Downgrades Marqeta to Hold, Lowers Price Target to $4

BTIG analyst Sean Lavin downgrades Tactile Systems Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TCMD#NASDAQ">TCMD</a>) from Buy to Neutral.

TCMD

BTIG Downgrades Tactile Systems Tech to Neutral

INGR

Ingredion Now Expects FY24 Net Sales To Be Down Mid-Single-Digits (Prior View: Down Low Single-Digits), Excluding Effects Of Sale Of South Korea Business

Ingredion Raises FY24 Adjusted EPS Outlook From $9.70 - $10.20 To $10.35 - $10.65, Est $9.97

2024 Financial Guidance
The Company is updating certain metrics for its full-year 2024 guidance, as detailed in the table below:
<figure class="table"> 
<table>
<tbody>
<tr>
<td colspan="1" rowspan="1">Financial Metric</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">Prior FY 2024 Guidance</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">Updated FY 2024 Guidance</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Revenues</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">$935 million to $955 million</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">$930 million to $940 million</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Adjusted EBITDA</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">$580 million to $595 million</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">$580 million to $590 million</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Interest expense</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">$320 million to $330 million</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">(unchanged)</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Cash flow from operations</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">$135 million to $150 million</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">$135 million to $145 million</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Capital expenditures</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">$120 million to $130 million</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">(unchanged)</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Depreciation</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">$80 million to $90 million</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">(unchanged)</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Amortization of intangible assets</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">$345 million to $350 million</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">(unchanged)</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Effective tax rate</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">25% to 28%</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">(unchanged)</td>
</tr>
</tbody>
</table>
</figure>

Health Care

MPLN

MultiPlan Expects 2024 Revenues Of $930M-$940M Compared With Prior Guidance $935M-$955M And Consensus Of $939.207M

Patria Investments (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PAX#NASDAQ">PAX</a>) reported quarterly earnings of $0.23 per share which missed the analyst consensus estimate of $0.24 by 4.17 percent. This is unchanged from the same period last year. The company reported quarterly sales of $77.700 million which beat the analyst consensus estimate of $76.058 million by 2.16 percent. This is a 25.93 percent increase over sales of $61.700 million the same period last year.

Earnings Beats

Patria Investments Q3 2024 Adj. EPS $0.23 Misses $0.24 Estimate, Sales $77.700M Beat $76.058M Estimate

Bernstein analyst Nikhil Devnani upgrades eBay (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EBAY#NASDAQ">EBAY</a>) from Market Perform to Outperform and announces $70 price target.

EBAY

Bernstein Upgrades eBay to Outperform, Announces $70 Price Target

2024 Financial Guidance
<ul>
<li>2024 total sales growth is now expected to be 4% to 5% over 2023, compared with prior guidance of 4% to 6% growth.</li>
<li>2024 non-GAAP diluted EPS attributable to Henry Schein, Inc. is now expected to be $4.74 to $4.82, compared with prior guidance of $4.70 to $4.82, and reflects growth of 5% to 7% compared with 2023 non-GAAP diluted EPS of $4.50.</li>
<li>2024 Adjusted EBITDA is expected to grow in the low-double-digit percentages versus 2023 Adjusted EBITDA, and is unchanged compared to prior guidance.</li>
</ul>

HSIC

Henry Schein Expects 2024 Adjusted EPS Of $4.74 To $4.82 Compared With Prior Guidance Of $4.70-$4.82 And Consensus Of $4.75

On Monday, November 4th, U.S. markets closed lower after a volatile session as investors braced for a pivotal week with the U.S. presidential election and the Federal Reserve&#8217;s policy announcement. A poll showing Kamala Harris leading in Iowa impacted &#8220;Trump trades,&#8221; adding market uncertainty amid expectations of delayed election results.
Economic data showed that U.S. factory orders dropped by 0.5% in September, reaching $584.2 billion, following a revised 0.8% decrease in August.
Most S&amp;P 500 sectors closed lower, led by losses in utilities, communication services, and financials, while energy and real estate stocks rose.
The Dow Jones Industrial Average dipped 0.61% to close at 41,794.60, the S&amp;P 500 fell 0.28% to 5,712.69, and the Nasdaq Composite declined 0.33% to finish at 18,179.98.
Asia Markets Today
<ul>
<li>On Tuesday, Japan&#8217;s Nikkei 225 gained 1.42% and ended the session at 38,595.50, led by gains in the Glass, Transportation Equipment, and Banking sectors.</li>
<li>Australia&#8217;s S&amp;P/ASX 200 declined 0.40% and ended the day at 8,131.80, led by losses in the Gold, Utilities, and Financial sectors.</li>
<li>India&#8217;s Nifty 50 traded higher by 0.85% at 24,199.05, and Nifty 500 was up 0.63% at 22,661.00, led by gains in the Metals, Banking, and Oil &amp; Gas sectors shares.</li>
<li>China&#8217;s Shanghai Composite rose 2.32% to close at 3,386.99, and the Shenzhen CSI 300 gained 2.53%, finishing the day at 4,044.57.</li>
<li>Hong Kong&#8217;s Hang Seng climbed 2.14% and closed the session at 21,006.97.</li>
</ul>
Eurozone at 05.30 AM ET
<ul>
<li>The European STOXX 50 index was up 0.05%.</li>
<li>Germany&#8217;s DAX declined 0.01%.</li>
<li>France&#8217;s CAC rose 0.04%.</li>
<li>U.K.'sU.K.&#8217;s FTSE 100 index traded higher by 0.25%.</li>
</ul>
Commodities at 05.30 AM ET
<ul>
<li>Crude Oil WTI was trading higher by 0.35% at $71.73/bbl, and Brent was up 0.36% at $75.33/bbl.</li>
<li>Oil prices stayed within a narrow range as markets awaited the U.S. presidential election, following a 2% rise after OPEC+ delayed a planned December production increase.</li>
<li>Natural Gas declined 0.36% to $2.771.</li>
<li>Gold was trading higher by 0.10% at $2,748.80, Silver gained 0.48% to $32.767, and Copper rose 0.85% to $4.4688.</li>
</ul>
U.S. Futures at 05.30 AM ET
Dow futures were up 0.13%, S&amp;P 500 futures gained 0.17%, and Nasdaq 100 Futures rose 0.27%.
Forex at 05.30 AM ET
<ul>
<li>The U.S. dollar index fell 0.12% to 103.77, the USD/JPY was up 0.05% to 152.20, and the USD/AUD declined 0.49% to 1.5110.</li>
<li>The dollar softened as election volatility spiked while traders awaited the Fed&#8217;s rate decision.</li>
</ul>
Photo by Pavel Bobrovskiy via Shutterstock

Asia

Emerging Markets

Eurozone

Futures

Commodities

Forex

ADIV

AGOV

ASHR

BBEU

BOIL

CQQQ

PowerShares DBmmodity Index Optimum Yield Diversified Fund

EEMA

FLAX

CurrencyShares British Pound Sterling Trust

IEMG

IEUR

KraneShares Trust KraneShares S&P Pan Asia Dividend Aristocrats Index ETF

KDIV

SPEM

USDU

PowerShares DB US Dollar Index Bullish Fund

On US Election Day, Asia Mostly In Green, Europe Mixed, Dollar Softens - Global Markets Today While US Slept

Gartner Raises FY24 Outlook: Sees Adjusted EPS Of $11.75 Vs. $11.68 Estimate (Prior View: $11.05), Projects Total Revenues Of $6.225B Vs. $6.23B Estimate (Prior View: $6.20B)

Zymeworks Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZYME#NASDAQ">ZYME</a>), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced that the first patient has been dosed in the company's first-in-human Phase 1 trial (<a href="https://www.globenewswire.com/Tracker?data=aHp-cuqHnmx8fC7lx89j8ZNJGMRAt_6zpxNTIBa9WLT2Pxo3_LUFvwDbbRLrv5itaRID_CNIJb4BLuhre6p5HfousB7RwUh-1SbW9cMtgjs=">NCT06555744</a>) to evaluate the safety and tolerability of the investigational therapy ZW191 in the treatment of advanced folate receptor-⍺ (FR⍺)-expressing solid tumors including ovarian, endometrial, and non-small cell lung (NSCLC) cancers.
"Our team is excited to initiate this important clinical trial to assess the safety and tolerability of ZW191, our first antibody-drug conjugate utilizing ZD06519, our novel proprietary payload, in patients with difficult-to-treat cancers," said Jeff Smith, M.D., FRCP, Executive Vice President and Chief Medical Officer at Zymeworks. "This global study represents a significant milestone in our mission to bring innovative and urgently needed therapies to patients in need. This announcement also follows the recent initiation of our Phase 1 trial of ZW171, marking an additional important step forward in advancing the many promising therapies in our wholly-owned pipeline."
FRα is found in ~75% of high-grade serous ovarian carcinomas1 and ~70% of lung adenocarcinomas2. In data presented at the American Association for Cancer Research (AACR) Annual Meeting in 2024, ZW191 was associated with greater anti-tumor activity compared to benchmark in FRα-expressing tumor models and was well-tolerated in cynomolgus monkeys up to 60 mg/kg3.
The Phase 1 trial is a two-part, multi-center, global study that aims to enroll 145 adult patients with advanced FR⍺-expressing cancers. The Company expects to enroll patients at investigator sites in North America, Europe, and the Asia-Pacific region. Part one of the study will evaluate the safety and tolerability of ZW191 and involve dose escalation in patients with advanced ovarian, endometrial, and NSCLC cancers, with secondary endpoints assessing pharmacokinetics and confirmed objective response rate. Part two of the study will further evaluate safety and explore the potential anti-tumor activity of ZW191.

ZYME

Zymeworks Begins Human Trials for New Cancer Therapy Targeting Ovarian and Lung Tumors

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
We&rsquo;re diving into the biggest pre-market stock movers that traders need to know about on Friday morning!



Moving stocks this morning are earnings reports, shutdown plans, clinical trial data and more.



Let&rsquo;s get into that news below!



<h2>Biggest Pre-Market Stock Movers: 10 Top Gainers</h2>



<ol><li>Akanda (NASDAQ:<a href="https://investorplace.com/stock-quotes/akan-stock-quote/">AKAN</a>) stock is rocketing more than 94 % with heavy trading <a href="https://www.nasdaq.com/press-release/akanda-announces-stock-consolidation-2024-05-21">after a reverse split</a>.</li>



<li>Netcapital (NASDAQ:<a href="https://investorplace.com/stock-quotes/ncpl-stock-quote/">NCPL</a>) shares are soaring over 71% alongside strong pre-market trading.</li>



<li>Cue Health (NASDAQ:<a href="https://investorplace.com/stock-quotes/hlth-stock-quote/">HLTH</a>) stock is surging more than 42% <a href="https://finance.yahoo.com/news/cue-health-lay-off-remaining-165945667.html">despite shutdown plans</a>.</li>



<li>Verastem (NASDAQ:<a href="https://investorplace.com/stock-quotes/vstm-stock-quote/">VSTM</a>) shares are rising over 35% on <a href="https://seekingalpha.com/news/4110109-verastem-stock-rallies-on-positive-data-for-pancreatic-cancer-drug-combo">positive pancreatic cancer drug data</a>.</li>



<li>Yoshitsu (NASDAQ:<a href="https://investorplace.com/stock-quotes/tklf-stock-quote/">TKLF</a>) stock is gaining more than 31% with heavy pre-market trading today.</li>



<li>Windtree Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/wint-stock-quote/">WINT</a>) shares are climbing over 24% despite a lack of news today.</li>



<li>Blue Star Foods (NASDAQ:<a href="https://investorplace.com/stock-quotes/bsfc-stock-quote/">BSFC</a>) stock is increasing more than 23% with strong trading on Friday.</li>



<li>Innovative Eyewear (NASDAQ:<a href="https://investorplace.com/stock-quotes/lucy-stock-quote/">LUCY</a>) shares are heading over 18% higher with heavy trading today.</li>



<li>Merus (NASDAQ:<a href="https://investorplace.com/stock-quotes/mrus-stock-quote/">MRUS</a>) stock is jumping 18% after reporting plans for its <a href="https://www.nasdaq.com/press-release/merus-announces-publication-of-abstracts-for-presentation-at-the-2024-ascor-annual-0">annual shareholder meeting</a>.</li>



<li>OneMedNet (NASDAQ:<a href="https://investorplace.com/stock-quotes/onmd-stock-quote/">ONMD</a>) shares are up 17% as it <a href="https://investorplace.com/2024/05/why-is-onemednet-onmd-stock-up-150-today/">continues to rally today</a>.</li>
</ol><h2>10 Top Losers</h2>



<ol><li>Tharimmune (NASDAQ:<a href="https://investorplace.com/stock-quotes/thar-stock-quote/">THAR</a>) stock is crashing more than 93% ahead of a <a href="https://www.nasdaq.com/press-release/tharimmune-announces-1-for-15-reverse-stock-split-2024-05-22">reverse stock split</a>.</li>



<li>Soluna (NASDAQ:<a href="https://investorplace.com/stock-quotes/slnh-stock-quote/">SLNH</a>) shares are plummeting over 43% without any clear news today.</li>



<li>Sensei Biotherapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/snse-stock-quote/">SNSE</a>) stock is diving more than 32% alongside <a href="https://www.nasdaq.com/press-release/sensei-biotherapeutics-presents-promising-clinical-data-from-phase-1-dose-escalation">Phase 1 clinical trial data</a>.</li>



<li>Barnes &amp; Noble Education (NYSE:<a href="https://investorplace.com/stock-quotes/bned-stock-quote/">BNED</a>) shares are tumbling over 22% <a href="https://www.businesswire.com/news/home/20240523398847/en/Barnes-Noble-Education-Announces-Preliminary-Fiscal-Year-2024-Results">alongside preliminary earnings</a>.</li>



<li>Cia Energetica DE Minas (NYSE:<a href="https://investorplace.com/stock-quotes/cig-stock-quote/">CIG</a>) stock is taking a more than 21% beating on Friday morning.</li>



<li>Summit Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/smmt-stock-quote/">SMMT</a>) shares are sliding 19% this morning.</li>



<li>Zoomcar (NASDAQ:<a href="https://investorplace.com/stock-quotes/zcar-stock-quote/">ZCAR</a>) stock is dropping over 14% after <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=318343841&amp;type=PDF&amp;symbol=ZCAR&amp;cdn=6950f0ca229d5d524e85e29caeb5189a&amp;companyName=Zoomcar+Holdings+Inc.&amp;formType=8-K&amp;formDescription=Current+report+pursuant+to+Section+13+or+15%28d%29&amp;dateFiled=2024-05-23">issuing an unsecured note</a>.</li>



<li>Akoustis Technologies (NASDAQ:<a href="https://investorplace.com/stock-quotes/akts-stock-quote/">AKTS</a>) shares are decreasing more than 14% <a href="https://investorplace.com/2024/05/why-is-akoustis-technologies-akts-stock-up-158-today/">following a recent rally</a>.</li>



<li>Roadzen (NASDAQ:<a href="https://investorplace.com/stock-quotes/rdzn-stock-quote/">RDZN</a>) stock is falling 13% on Friday.</li>



<li>Solowin (NASDAQ:<a href="https://investorplace.com/stock-quotes/swin-stock-quote/">SWIN</a>) shares close out our pre-market stock movers down close to 13%.</li>
</ol>On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT802110">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/2024/05/todays-biggest-pre-market-stock-movers-10-top-gainers-and-losers-on-friday-may-24th/">Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Tharimmune&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/thar-stock-quote/">THAR</a>) stock is on the move Friday as investors prepare for the company&rsquo;s shares to undergo a reverse split when markets close today.



Tharimmune&nbsp;is enacting a <a href="https://www.nasdaq.com/press-release/tharimmune-announces-1-for-15-reverse-stock-split-2024-05-22">one-for-15 reverse stock split</a> for THAR shares. The shares will still trade under the THAR ticker but will switch to the new CUSIP number 432705309.



Tharimmune&nbsp;notes that this split will see it consolidate every 15 shares of its stock into a single share. The company says that this will leave it with 785,978 shares of THAR stock after the reverse split is complete.



<h2>What&rsquo;s Behind the THAR Reverse Stock Split?</h2>



Tharimmune&nbsp;is moving forward with this reverse stock split to boost the price of its shares. The company wants to boost its share price to reach the $1 minimum bid required to remain on The Nasdaq Capital Market. The stock was trading for 33 cents per share when markets closed yesterday.



Tharimmune&nbsp;wants to remain listed as it&rsquo;s still only a clinical-stage biotechnology company. That means it doesn&rsquo;t have a product to sell just yet. Remaining publicly listed is its goal leading up to a potential drug candidate release.



THAR stock is up 3.7% as of Friday morning ahead of the reverse split. However, the company&rsquo;s shares were down 34.5% year-to-date when markets closed on Thursday.



Investors will find more of the most recent stock market stories below!



We have all of the hottest stock market news traders need to know about on Friday! A few examples include what&rsquo;s happening with shares of Netcapital&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/ncpl-stock-quote/">NCPL</a>) and Akanda&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/akan-stock-quote/">AKAN</a>) stock as well as the biggest pre-market stock movers this morning. All of this news is ready at the links below!



<h2>More Friday Stock Market News</h2>



<ul><li><a href="https://investorplace.com/2024/05/why-is-netcapital-ncpl-stock-up-73-today/">Why Is Netcapital (NCPL) Stock Up 73% Today?</a></li>



<li><a href="https://investorplace.com/2024/05/why-is-akanda-akan-stock-up-133-today/">Why Is Akanda (AKAN) Stock Up 133% Today?</a></li>



<li><a href="https://investorplace.com/2024/05/todays-biggest-pre-market-stock-movers-10-top-gainers-and-losers-on-friday-may-24th/">Today&rsquo;s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on&nbsp;Friday</a></li>
</ul>On Penny Stocks and Low-Volume Stocks:&#8239;With only the rarest exceptions, InvestorPlace does not publish commentary about companies that have a market cap of less than $100 million or trade less than 100,000 shares each day. That&rsquo;s because these &ldquo;penny stocks&rdquo; are frequently the playground for scam artists and market manipulators. If we ever do publish commentary on a low-volume stock that may be affected by our commentary, we demand that&#8239;InvestorPlace.com&rsquo;s writers disclose this fact and warn readers of the risks.



Read More:&#8239;Penny Stocks &mdash;&nbsp;<a href="https://investorplace.com/2014/05/fraud-penny-stocks-scams/" target="_blank">How to Profit Without Getting Scammed</a>



On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT802110">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/2024/05/why-is-tharimmune-thar-stock-moving-today/">Why Is Tharimmune (THAR) Stock Moving Today?</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Why Is Tharimmune (THAR) Stock Moving Today?

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Sensei Biotherapeutics&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/snse-stock-quote/">SNSE</a>) stock is falling on Friday after it failed to impress investors with its latest Phase 1/2 clinical trial data for SNS-101.



SNS-101 is a human monoclonal antibody targeting the immune checkpoint VISTA. The company notes this has it being developed to treat solid cancer tumors.



The bad news for Sensei Biotherapeutics comes from its <a href="https://www.nasdaq.com/press-release/sensei-biotherapeutics-presents-promising-clinical-data-from-phase-1-dose-escalation">results in this trial</a>. The company notes that only a few patients of the 34 treated showed signs of improvement. That doesn&rsquo;t seem to be sitting well with SNSE stockholders today.



Dr.&nbsp;Shiraj Sen, a principal&nbsp;investigator in the SNS-101 study, said the following about the results.




&ldquo;The data show encouraging signs of clinical activity in a heterogeneous population of patients with advanced solid tumors, where you typically wouldn&rsquo;t expect to see clinical responses, especially in microsatellite stable colorectal and endometrial tumors.&rdquo;




<h2>SNSE Stock Market Movement on Friday</h2>



SNSE stock is seeing a decent amount of trading on Friday morning. This has more than 160,000 shares of the stock changing hands as of this writing. That&rsquo;s closing in on its daily average trading volume of about 208,000 shares.



SNSE stock is down 39.8% as of Friday morning. However, shares were up 83.5% year-to-date when markets closed yesterday.



Investors looking for more of the most recent stock market stories are in luck!



We have all of the hottest stock market news traders need to know about on Friday! That includes what&rsquo;s going on with shares of Tharimmune&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/thar-stock-quote/">THAR</a>) stock, Netcapital&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/ncpl-stock-quote/">NCPL</a>)&nbsp;stock and Akanda&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/akan-stock-quote/">AKAN</a>) stock today. All of this info is good to go at the links below!



<h2>More Stock Market News for Friday</h2>



<ul><li><a href="https://investorplace.com/2024/05/why-is-tharimmune-thar-stock-moving-today/">Why Is Tharimmune (THAR) Stock Moving Today?</a></li>



<li><a href="https://investorplace.com/2024/05/why-is-netcapital-ncpl-stock-up-73-today/">Why Is Netcapital (NCPL) Stock Up 73% Today?</a></li>



<li><a href="https://investorplace.com/2024/05/why-is-akanda-akan-stock-up-133-today/">Why Is Akanda (AKAN) Stock Up 133% Today?</a></li>
</ul>On Penny Stocks and Low-Volume Stocks:&#8239;With only the rarest exceptions, InvestorPlace does not publish commentary about companies that have a market cap of less than $100 million or trade less than 100,000 shares each day. That&rsquo;s because these &ldquo;penny stocks&rdquo; are frequently the playground for scam artists and market manipulators. If we ever do publish commentary on a low-volume stock that may be affected by our commentary, we demand that&#8239;InvestorPlace.com&rsquo;s writers disclose this fact and warn readers of the risks.



Read More:&#8239;Penny Stocks &mdash;&nbsp;<a href="https://investorplace.com/2014/05/fraud-penny-stocks-scams/" target="_blank">How to Profit Without Getting Scammed</a>



On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT802110">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/2024/05/why-is-sensei-biotherapeutics-snse-stock-down-40-today/">Why Is Sensei Biotherapeutics (SNSE) Stock Down 40% Today?</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Why Is Sensei Biotherapeutics (SNSE) Stock Down 40% Today?

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Verastem (NASDAQ:<a href="https://investorplace.com/stock-quotes/vstm-stock-quote/">VSTM</a>) stock is falling hard on Friday following the release of new clinical trial data for its metastatic pancreatic cancer treatment.



The company is <a href="https://finance.yahoo.com/news/verastem-oncology-announces-positive-initial-210100621.html">conducting a Phase 1/2 clinical trial</a> of avutometinib plus defactinib in combination with gemcitabine and Nab-paclitaxel. The results were positive and that initially saw VSTM stock rally higher this morning.



However, investors quickly noticed the safety data included in these results. 19 of the 41 patients in the trial suffered from emergent serious adverse events. That includes 11 with grade &ge;3 events. Among these were blood bilirubin increase, biliary obstruction, febrile neutropenia, pulmonary embolism, sepsis, anaemia, pneumoperitoneum, septic shock, skin infection, malignant neoplasm progression and vomiting.



John Hayslip, Chief Medical Officer at Verastem, said the following about the clinical trial results.




&ldquo;Metastatic pancreatic cancer continues to be a challenging cancer to treat and these data support the intent behind the Therapeutic Accelerator Award that we received from PanCAN to develop new therapies faster and more efficiently than in historical studies.&rdquo;




<h2>VSTM Stock Movement on Friday</h2>



VSTM stock is experiencing heavy trading on Friday alongside this data. That has more than 10 million shares traded as of this writing. This is a massive surge compared to its daily average trading volume of about 134,000 shares.



VSTM stock is down 61.7% as of Friday morning!



Investors will want to keep reading for more of the most recent stock market stories!



We have all of the hottest stock market news traders need to know about on Friday! Among that is what has shares of Sensei Biotherapeutics&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/snse-stock-quote/">SNSE</a>), Tharimmune&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/thar-stock-quote/">THAR</a>) and Netcapital&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/ncpl-stock-quote/">NCPL</a>) stock moving today. All of this news is available down below!



<h2>More Friday Stock Market News</h2>



<ul><li><a href="https://investorplace.com/2024/05/why-is-sensei-biotherapeutics-snse-stock-down-40-today/">Why Is Sensei Biotherapeutics (SNSE) Stock Down 40% Today?</a></li>



<li><a href="https://investorplace.com/2024/05/why-is-tharimmune-thar-stock-moving-today/">Why Is Tharimmune (THAR) Stock Moving Today?</a></li>



<li><a href="https://investorplace.com/2024/05/why-is-netcapital-ncpl-stock-up-73-today/">Why Is Netcapital (NCPL) Stock Up 73% Today?</a></li>
</ul>On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT802110">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/2024/05/why-is-verastem-vstm-stock-down-62-today/">Why Is Verastem (VSTM) Stock Down 62% Today?</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Why Is Verastem (VSTM) Stock Down 62% Today?

Tharimmune announces $2.08M private placement

Tharimmune files for 1M common stock offering by selling stockholders

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Tharimmune (NASDAQ:<a href="https://investorplace.com/stock-quotes/thar-stock-quote/">THAR</a>) just reported results for the second quarter of 2024.<ul><li>Tharimmune reported earnings per share of -$2.42.</li><li>The company did not report any revenue for the quarter.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/thar-stock-earnings-tharimmune-for-q2-of-2024/">THAR Stock Earnings: Tharimmune Reported Results for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

THAR Stock Earnings: Tharimmune Reported Results for Q2 2024

Tharimmune ( ($THAR) ) has provided an announcement. Tharimmune, Inc. has secured an exclusive license from Intract Pharma to develop an oral versi...

Tharimmune Expands Immunology Pipeline with Intract License

Tharimmune ( ($THAR) ) has shared an announcement. Tharimmune, Inc. has announced its intent to acquire Intract Pharma Limited, aiming to purchase ...

Tharimmune Announces Intent to Acquire Intract Pharma

Tharimmune (THAR) presented new TH104 Phase 1 data at the American College of Gastroenterology 2024 Annual Scientific Meeting, underway in Philadel...

Comments

Tharimmune

Tharimmune (THAR) Opzioni

No option chain data available. Please try again later

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO